An evidence-based approach to the diagnosis and staging of pancreatic cancer

Pancreatology

Volumn 5, Issue 6, 2005, Pages 576-590

  Katz, Matthew H ^a   Savides, Thomas J ^b   Moossa, A R ^a   Bouvet, Michael ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CA 19 9; Computed tomography; Diagnosis; Endoscopic ultrasonography; Pancreatic cancer; Staging

Indexed keywords

CA 19-9 ANTIGEN;

ABDOMEN; ALGORITHM; ANTIGEN DETECTION; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; HUMAN; LAPAROSCOPY; LYMPH NODE METASTASIS; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RELIABILITY; SYSTEMATIC REVIEW; TUMOR VOLUME;

EID: 26044460919     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000087500     Document Type: Article

References (132)

1. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF: An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003;196:954-964.
2. Breslin TM, Hess KR, Harbison DB, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
3. Bouvet M, Gamagami RA, Gilpin EA, et al: Factors influencing survival after resection for periampullary neoplasms. Am J Surg 2000;180:13-17.
4. Katz MH, Bouvet M, Al-Refaie W, Gilpin EA, Moossa AR: Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis. Hepatogastroenterology 2004;51:842-846.
5. Yeo CJ, Cameron JL, Sohn TA, et al: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-257, discussion 257-260.
6. Furukawa H, Okada S, Saisho H, et al: Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996;78:986-990.
7. Yeo CJ, Cameron JL, Lillemoe KD, et al: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731, discussion 731-723.
8. Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
9. Yeo CJ: Pancreatic cancer: 1998 update. J Am Coll Surg 1998;187:429-442.
10. Lillemoe KD: Current management of pancreatic carcinoma. Ann Surg 1995;221:133-148.
11. Exocrine pancreas; in American Joint Committee on Cancer: AJCC Cancer Staging Manual, ed 6. New York. Springer, 2002, pp 157-164.
12. Leach SD, Lee JE, Charnsangavej C, et al: Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85:611-617.
13. Harrison LE, Brennan MF: Portal vein involvement in pancreatic cancer: a sign of unresectability? Adv Surg 1997;31:375-394.
14. Moossa AR, Lewis MH, Bowie JD: Clinical features and diagnosis of pancreatic cancer; in Moossa AR (ed): Tumors of the Pancreas. Baltimore, Williams & Wilkins, 1980, pp 397-414.
15. Bouvet M, Binmoeller KF, Moossa AR: Diagnosis of adenocarcinoma of the pancreas; in Cameron JL (ed): American Cancer Society Atlas of Clinical Oncology: Pancreatic Cancer. Hamilton, Decker, 2001.
16. Palsson B, Masson P, Andren-Sandberg A: Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer. Eur J Surg Oncol 1997;23:151-156.
17. DiMagno EP, Malagelada JR, Taylor WF, Go VL: A prospective comparison of current diagnostic tests for pancreatic cancer. N Engl J Med 1977;297:737-742.
18. Moossa AR, Levin B: The diagnosis of 'early' pancreatic cancer: the University of Chicago experience. Cancer 1981;47(6 suppl):1688-1697.
19. Warren KW, Jefferson MF: Carcinoma of the exocrine pancreas; in Carey LC (ed): The Pancreas. St. Louis, Mosby, 1973, pp 243-294.
20. Sohn TA, Yeo CJ, Cameron JL, et al: Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
21. Brand R: The diagnosis of pancreatic cancer. Cancer J 2001;7:287-297.
22. Podolsky DK: Serologic markers in the diagnosis and management of pancreatic carcinoma. World J Surg 1984;8:822-830.
23. Satake K, Takeuchi T, Homma T, Ozaki H: CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994;9:703-706.
24. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC Choi KW: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.
25. Lynch HT, Smyrk T, Kern SE, et al: Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-275.
26. Rulyak SJ, Brentnall TA, Lynch HT, Austin MA: Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 2003;98:798-804.
27. Giardiello FM, Brensinger JD, Tersmette AC, et al: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-1453.
28. Giardiello FM, Offerhaus GJ, Lee DH, et al: Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34:1394-1396.
29. Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-5364.
30. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF: Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985;52:271-273.
31. Lowenfels AB, Maisonneuve P, Whitcomb DC: Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am 2000;84:565-573.
32. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M: Familial pancreatic cancer. Cancer J 2001;7:266-273.
33. Klein AP, Brune KA, Petersen GM, et al: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-2638.
34. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA: Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003;124:1292-1299.
35. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP: Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001;286:169-170.
36. Canto MI, Goggins M, Yeo CJ, et al: Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-621.
37. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-255.
38. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA: Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003;57:23-29.
39. Gandolfi L, Torresan F, Solmi L, Puccetti A: The role of ultrasound in biliary and pancreatic diseases. Eur J Ultrasound 2003;16:141-159.
40. Pollock D, Taylor KJ: Ultrasound scanning in patients with clinical suspicion of pancreatic cancer: a retrospective study. Cancer 1981;47(6 suppl):1662-1665.
41. Karlson BM, Ekbom A, Lindgren PG, Kallskog V, Rastad J: Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis. Radiology 1999;213:107-111.
42. Bottger TC, Boddin J, Duber C, Heintz A, Kuchle R, Junginger T: Diagnosing and staging of pancreatic carcinoma - what is necessary? Oncology 1998;55:122-129.
43. Rosch T, Braig C, Gain T, et al: Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 1992;102:188-199.
44. Tomiyama T, Ueno N, Tano S, Wada S, Kimura K: Assessment of arterial invasion in pancreatic cancer using color Doppler ultrasonography. Am J Gastroenterol 1996;91:1410-1416.
45. Campbell JP, Wilson SR: Pancreatic neoplasms: how useful is evaluation with US? Radiology 1988;167:341-344.
46. Katz M, Moossa AR, Bouvet M: Serologic diagnosis of pancreatic cancer; in Von Hoff DD, Evans DB, Hruban RH (eds): Pancreatic Cancer. Boston, Jones & Bartlett, 2005, pp 235-249.
47. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-971.
48. Del Villano BC, Brennan S, Brock P, et al: Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549-552.
49. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Makela O: Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984;37:218-222.
50. Sakahara H, Endo K, Nakajima K, et al: Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986;57:1324-1326.
51. Steinberg WM, Gelfand R, Anderson KK, et al: Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-349.
52. Piantino P, Andriulli A, Gindro T, et al: CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986;81:436-439.
53. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, Jalanko H: Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986;53:197-202.
54. Malesci A, Montorsi M, Mariani A, et al: Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992;7:497-502.
55. Safi F, Roscher R, Beger HG: Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989;36:419-423.
56. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK: Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-709.
57. Ritts RE Jr, Nagorney DM, Jacobsen DJ, Talbot RW, Zurawski VR Jr: Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994;9:707-716.
58. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E: The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000;47:1750-1752.
59. Andriulli A, Gindro T, Piantino P, et al: Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers. Digestion 1986;33:26-33.
60. Malesci A, Tommasini MA, Bonato C, et al: Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92:60-67.
61. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-2316.
62. Ritts RE, Pitt HA: CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998;7:93-101.
63. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-355.
64. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J: Serum CA19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 1996;43:710-713.
65. Richter JM, Christensen MR, Rustgi AK, Silverstein MD: The clinical utility of the Ca19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost-effectiveness analysis. Arch Intern Med 1989;149:2292-2297.
66. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-5503.
67. von Rosen A, Linder S, Harmenberg U, Pegert S: Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993;8:160-165.
68. Albert MB, Steinberg WM, Henry JP: Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-1225.
69. Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-479.
70. Del Favero G, Fabris C, Plebani M, et al: CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986;57:1576-1579.
71. Benamouzig R, Buffet C, Fourre C, Ink O, Moati F, Etienne JP: Serum levels of carbohydrate antigenic determinant (CA19-9) in obstructive jaundice. Dig Dis Sci 1989;34:1640-1642.
72. Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-955; discussion 955-956.
73. Barone D, Onetto M, Conio M, et al: CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 1988;3:95-100.
74. Fabris C, Del Favero G, Basso D, et al: Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Am J Gastroenterol 1988;83:549-553.
75. Horton KM: Multidetector CT and three-dimensional imaging of the pancreas: state of the art. J Gastrointest Surg 2002;6:126-128.
76. Horton KM, Fishman EK: Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:1263-1272.
77. Tamm E, Charnsangavej C: Pancreatic cancer: current concepts in imaging for diagnosis and staging. Cancer J 2001;7:298-311.
78. Bluemke DA, Fishman EK: CT and MR evaluation of pancreatic cancer. Surg Oncol Clin N Am 1998;7:103-124.
79. Kim T, Murakami T, Takamura M, et al: Pancreatic mass due to chronic pancreatitis: correlation of CT and MR imaging features with pathologic findings. AJR Am J Roentgenol 2001;177:367-371.
80. McNulty NJ, Francis IR, Platt JF, Cohan RH, Korobkin M, Gebremariam A: Multi-detector row helical CT of the pancreas: Effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 2001;220:97-102.
81. Prokesch RW, Chow LC, Beaulieu CF, et al: Local staging of pancreatic carcinoma with multi-detector row CT: use of curved planar reformations initial experience. Radiology 2002;225:759-765.
82. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M: Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373-378.
83. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J: Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-1443.
84. Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C: Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996;21:202-206.
85. Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al: Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167:104-111; discussion 111-103.
86. Freeman ML, DiSario JA, Nelson DB, et al: Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54:425-434.
87. Freeman ML, Nelson DB, Sherman S, et al: Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-918.
88. Povoski SP, Karpeh MS Jr, Conlon KC, Blumgart LH, Brennan MF: Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg 1999;230:131-142.
89. Sohn TA, Yeo CJ, Cameron JL, Pitt HA, Lillemoe KD: Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 2000;4:258-267; discussion 267-258.
90. Erickson RA: Endoscopic diagnosis and staging: endoscopic ultrasound, endoscopic retrograde cholangiopancreatography; in Evans DB, Abbruzzese JL, Pisters PW (eds): Pancreatic Cancer. New York, Springer, 2001, pp 97-112.
91. Gress F, Savides T, Cummings O, et al: Radial scanning and linear array endosonography for staging pancreatic cancer: a prospective randomized comparison. Gastrointest Endosc 1997;45:138-142.
92. Eloubeidi MA, Chen VK, Eltoum IA, et al: Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol 2003;98:2663-2668.
93. Gress FG, Hawes RH, Savides TJ, et al: Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999;50:786-791.
94. Harewood GC, Wiersema LM, Halling AC, Keeney GL, Salamao DR, Wiersema MJ: Influence of EUS training and pathology interpretation on accuracy of EUS-guided fine needleaspirationofpancreaticmasses. Gastrointest Endosc 2002;55:669-673.
95. Legmann P, Vignaux O, Dousset B. et al: Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998;170:1315-1322.
96. Chen CH, Tseng LJ, Yang CC, Yeh YH: Preoperative evaluation of periampullary tumors by endoscopic sonography, transabdominal sonography, and computed tomography. J Clin Ultrasound 2001;29:313-321.
97. Mertz HR, Sechopoulos P, Delbeke D, Leach SD: EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:367-371.
98. Schwarz M, Pauls S, Sokiranski R, et al: Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective? Am J Surg 2001;182:243-249.
99. Brand B, Pfaff T, Binmoeller KF, et al: Endoscopic ultrasound for differential diagnosis of focal pancreatic lesions, confirmed by surgery. Scand J Gastroenterol 2000;35:1221-1228.
100. Shin HJ, Lahoti S, Sneige N: Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: The M.D. Anderson Cancer Center experience. Cancer 2002;96:174-180.
101. Eloubeidi MA, Jhala D, Chhieng DC, et al: Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 2003;99:285-292.
102. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD: The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997;45:387-393.
103. Moossa AR, Altorki N: Pancreatic biopsy. Surg Clin North Am 1983;63:1205-1214.
104. Micames C, Jowell PS, White R, et al: Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003;58:690-695.
105. Yasuda K, Mukai H, Nakajima M, Kawai K: Staging of pancreatic carcinoma by endoscopic ultrasonography. Endoscopy 1993;25:151-155.
106. Ahmad NA, Kochman ML, Lewis JD, et al: Endosonography is superior to angiography in the preoperative assessment of vascular involvement among patients with pancreatic carcinoma. J Clin Gastroenterol 2001;32:54-58.
107. Tierney WM, Francis IR, Eckhauser F, Elta G, Nostrant TT, Scheiman JM: The accuracy of EUS and helical CT in the assessment of vascular invasion by peripapillary malignancy. Gastrointest Endosc 2001;53:182-188.
108. Brugge WR, Lee MJ, Kelsey PB, Schapiro RH, Warshaw AL: The use of EUS to diagnose malignant portal venous system invasion by pancreatic cancer. Gastrointest Endosc 1996;43:561-567.
109. Rosch T, Dittler HJ, Strobel K, et al: Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapes. Gastrointest Endosc 2000;52:469-477.
110. Brugge WR: Pancreatic cancer staging. Endoscopic ultrasonography criteria for vascular invasion. Gastrointest Endosc Clin N Am 1995;5:741-753.
111. Meining A, Dittler HJ, Wolf A, et al: You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 2002;50:599-603.
112. Orlando LA, Kulasingam SL, Matchar DB: Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 2004;20:1063-1070.
113. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-199.
114. Papos M, Takacs T, Tron L, et al: The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med 2002;27:197-201.
115. 18F- fluorodeoxyglucose: diagnostic limitations. World J Surg 2000;24:1121-1129.
116. Kalady MF, Clary BM, Clark LA, et al: Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002;9:799-806.
117. Rose DM, Delbeke D, Beauchamp RD, et al: 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737; discussion 737-728.
118. Alazraki N: Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastrointest Surg 2002;6:136-138.
119. Ichikawa T, Haradome H, Hachiya J, et al: Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997;202:655-662.
120. Sheridan MB, Ward J, Guthrie JA, et al: Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 1999;173:583-590.
121. Conlon KC, Dougherty E, Klimstra DS, Coit DG, Turnbull AD, Brennan MF: The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134-140.
122. van Dijkum EJ, de Wit LT, van Delden OM, et al: Staging laparoscopy and laparoscopic ultrasonography in more than 400 patients with upper gastrointestinal carcinoma. J Am Coll Surg 1999;189:459-465.
123. Rau B, Hunerbein M, Schlag PM: Is there additional information from laparoscopic ultrasound in tumor staging? Dig Surg 2002;19:479-483.
124. Cuschieri A: Laparoscopy for pancreatic cancer: does it benefit the patient? Eur J Surg Oncol 1988;14:41-44.
125. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C: Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000;135:409-414; discussion 414-405.
126. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB: Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325-337.
127. Friess H, Kleeff J, Silva JC, Sadowski C, Baer HU, Buchler MW: The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998;186:675-682.
128. Fernandez-del Castillo C, Rattner DW, Warshaw AL: Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 1995;82:1127-1129.
129. Nieveen van Dijkum EJ, Romijn MG, Terwee CB, et al: Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann Surg 2003;237:66-73.
130. Lillemoe KD, Cameron JL, Hardacre JM, et al: Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230:322-328; discussion 328-330.
131. van den Bosch RP, van der Schelling GP, Klinkenbijl JH, Mulder PG, van Blankenstein M, Jeekel J: Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 1994;219:18-24.
132. van Wagensveld BA, Coene PP, van Gulik TM, Rauws EA, Obertop H, Gouma DJ: Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients. Br J Surg 1997;84:1402-1406.